Abstract 3099: Selective CDK2 inhibition with ECI830: preclinical characterization, efficacy, and on-target mechanism supported by biomarker and gene signature analysisOphélia Maertens, Samuel B. Ho, Eric Fang et al.|Cancer Research|2026Cited by 0